Protagonist Therapeutics (PTGX) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month target prices for Protagonist Therapeutics' shares. Their PTGX share price forecasts range from $28.00 to $41.00. On average, they anticipate the company's stock price to reach $35.67 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts.

Protagonist Therapeutics' stock was trading at $10.91 at the start of the year. Since then, PTGX stock has increased by 158.5% and is now trading at $28.20.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PTGX earnings forecast.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.02.

ETFs with the largest weight of Protagonist Therapeutics (NASDAQ:PTGX) stock in their portfolio include Innovator IBD Breakout Opportunities ETF (BOUT), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA Healthcare Momentum ETF (PTH), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), BlackRock Future Health ETF (BMED) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (8.04%), BlackRock Inc. (7.69%), BVF Inc. IL (6.60%), Farallon Capital Management LLC (4.57%), State Street Corp (4.22%) and Dimensional Fund Advisors LP (2.20%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg.
View institutional ownership trends.

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PTGX stock can currently be purchased for approximately $28.20.

Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $1.61 billion and generates $859,000.00 in revenue each year. The company earns $-127,390,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

The company employs 118 workers across the globe.

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com.